Business Context and Reporting Period
This Form 6-K filing by XTL Biopharmaceuticals Ltd. covers the month of June 2026. The report details the results of an Extraordinary General Meeting of Shareholders held on June 29, 2026, in Tel Aviv, Israel. The meeting was originally scheduled for June 22, 2026, but was adjourned due to a lack of quorum.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder approvals regarding a proposed transaction.
Material Changes and Corporate Actions
Shareholders approved four key resolutions at the June 29 meeting:
- Acquisition of Psyga Bio Ltd.: Approval to acquire between 80% and 100% of Psyga Bio Ltd.'s share capital, making XTL the controlling shareholder. Consideration includes Issued Shares and Milestone Warrants via private placement.
- Private Placement: Authorization for a private placement of up to US$1,500,000 from Mr. Alexander Rabinovitch and/or other investors, conditional on the consummation of the Psyga transaction.
- Capital Increase: Approval to increase authorized share capital by 2,900,000,000 shares, bringing the total authorized capital to 5,800,000,000 ordinary shares (par value NIS 0.1 each).
- Auditor Appointment: Appointment of BARZILY & CO. C.P.A as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Outlook, Risks, and Management Commentary
The filing indicates that the private placement funding is conditional upon the successful completion of the Psyga acquisition. The appointment of auditors for the 2025 fiscal year suggests ongoing operational continuity. No specific risks, contingencies, or unusual items beyond the standard conditions of the proposed transaction were detailed in this summary text.
Investor Verification Checklist
- Verify the final terms of the Share Purchase Agreement (SPA) with Psyga Bio Ltd.
- Confirm the actual amount raised from the private placement and the identity of participating investors.
- Monitor the timeline for the closing of the Psyga acquisition and the issuance of new shares.
- Review the full proxy statement for detailed valuation metrics regarding the Psyga transaction.